Cargando…
Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models
Therapeutic concepts exploiting tumor-specific antibodies are often established in pre-clinical xenograft models using immuno-deficient mice. More complex therapeutic paradigms, however, warrant the use of immuno-competent mice, that more accurately capture the relevant biology that is being exploit...
Autores principales: | Labrijn, Aran F., Meesters, Joyce I., Bunce, Matthew, Armstrong, Anthony A., Somani, Sandeep, Nesspor, Tom C., Chiu, Mark L., Altintaş, Işil, Verploegen, Sandra, Schuurman, Janine, Parren, Paul W. H. I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449386/ https://www.ncbi.nlm.nih.gov/pubmed/28559564 http://dx.doi.org/10.1038/s41598-017-02823-9 |
Ejemplares similares
-
Fab-arm exchange: What’s in a name?
por: Schuurman, Janine, et al.
Publicado: (2012) -
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021) -
Opening the door to innovation
por: Schuurman, Janine, et al.
Publicado: (2014) -
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020) -
Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches
por: Gramer, Michael J, et al.
Publicado: (2013)